Currently, the biotech M&A market is subject to a confluence of unique historic forces, both promoting and opposing M&A. Some of these forces include unprecedent M&A demand from big pharma due to the looming “patent cliff,” a largely flat XBI in 2024, an uncertain IPO market, a global economy turning the corner on inflation, a surge in biotech stockholder activism, and shifting political and policy priorities with the transition to the Trump Administration in the United States, including with respect to antitrust enforcement, drug pricing, cross border transactions and how the major US healthcare agencies will function under their new leadership. The impact of these forces will profoundly shape the industry in 2025 and beyond. Attend this session to gain valuable perspective about how these trends may affect your potential business development activities.